Search research articles
Contact Us
Filters
Showing results (1-10 of 266) with videos related to
Page
of 27
Sort By:
Hepatitis Research and Treatment
|
December 29, 2010
Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors
Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
January 7, 2016
[Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]
Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi
Annals of Laboratory Medicine
|
August 25, 2020
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
Nobuharu Tamaki, Masayuki Kurosaki, Rohit Loomba, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
March 30, 2022
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 19, 2021
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease
Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Journal of Medical Ultrasonics (2001)
|
June 24, 2021
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.
Journal of Surgical Oncology
|
June 3, 2015
Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis
Tomohiro Tanaka, Masayuki Kurosaki, Leslie B Lilly, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
July 27, 2023
Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real-world post-marketing surveillance in Japan
Hitoshi Yoshiji, Junto Suzuki, Masafumi Imasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 20, 2022
Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis
Shun Kaneko, Masayuki Kurosaki, Akemi Kurisu, et al.
Journal of Gastroenterology
|
May 11, 2020
Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
Isao Sakaida, Shuji Terai, Masayuki Kurosaki, et al.
Page
of 27
Search research articles
Search
Showing results (1-10 of 266) with videos related to
Sort By:
Page
of 27
Hepatitis Research and Treatment
|
December 29, 2010
Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors
Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
January 7, 2016
[Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]
Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi
Annals of Laboratory Medicine
|
August 25, 2020
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
Nobuharu Tamaki, Masayuki Kurosaki, Rohit Loomba, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
March 30, 2022
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 19, 2021
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease
Nobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Journal of Medical Ultrasonics (2001)
|
June 24, 2021
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.
Journal of Surgical Oncology
|
June 3, 2015
Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis
Tomohiro Tanaka, Masayuki Kurosaki, Leslie B Lilly, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
July 27, 2023
Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real-world post-marketing surveillance in Japan
Hitoshi Yoshiji, Junto Suzuki, Masafumi Imasaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 20, 2022
Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis
Shun Kaneko, Masayuki Kurosaki, Akemi Kurisu, et al.
Journal of Gastroenterology
|
May 11, 2020
Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
Isao Sakaida, Shuji Terai, Masayuki Kurosaki, et al.
Page
of 27